For UK media enquiries contact: Cheryl Pitcher
If you are a member of the working press and need an asset please email us and we will make every effort to respond as soon as possible.
Allergan Aesthetics’ response to the Department of Health and Social Care licensing of non-surgical cosmetic procedures in England.
Allergan Aesthetics, an AbbVie company, supports the responsible and compliant use of aesthetic medicine products in adults and welcomes the recently launched Consultation by the Department of Health and Social Care on the licensing of non-surgical cosmetic procedures in England.
Patient safety is paramount, and anyone considering or undergoing aesthetic procedures should expect a thorough consultation, including informed consent, conducted by a qualified practitioner.
Qualified training is of the utmost importance for aesthetics practitioners and Allergan Aesthetics’ comprehensive and progressive medical training delivered via the Allergan Medical Institute® aims to support the safe and effective use of our product range.
UK-AGNA-230300 September 2023
About Allergan Aesthetics
Allergan Aesthetics is an AbbVie (NYSE: ABBV) company that develops, manufactures, and markets a portfolio of leading aesthetics brands and products for consumers around the world.
The Allergan Aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more.
With its own research and development function focused on driving innovation in aesthetics, Allergan Aesthetics is committed to providing the most comprehensive science-based product offerings available.
JUVÉDERM® is marketed to people aged >18 years only
Adverse events should be reported. UK reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available at Google Play or Apple App stores. Irish healthcare professionals (HCPs) are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; website https://www.hpra.ie. Adverse events should also be reported to AbbVie on ProductSurveillance_EAME@allergan.com.
UK-AGNA-230229 Date of Preparation:- September 2023